GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

Fri, 09th Jul 2021 10:52

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Cambridge Cognition Holdings PLC, up 8.1% at 177.8 pence, 12-month range 35.1p-188p. Wins GBP1 million contract as cognitive assessment partner for a late phase cancer trial. Revenue from the contract is expected to be recognised over the next six years. "This is the second contract for a top ten pharmaceutical company with a strong pipeline of oncology products," the digital neuroscience company notes.

----------

Open Orphan, up 7.4% at 26.85p, 12-month range 11.5p-48p. Subsidiary hVIVO signs "significant" contract with AIM ImmunoTech Inc to test its antiviral candidate, Ampligen, using both the human Rhinovirus HRV and Influenza human challenge study models as part of a single study. This antiviral study will be conducted by hVIVO. The pharmaceutical services firm expects majority of revenue from the contract to be recognised in the current financial year. "As previously confirmed to the market, our London facilities are comprehensively prebooked throughout this year and into next year. As such, I am also delighted to confirm that we were solidly Ebitda profitable in H1 2021 and we remain on target for a profitable and successful 2021," says Open Orphan Executive Chair Cathal Friel.

----------

AIM - LOSERS

----------

Evgen Pharma PLC, down 30% at 5.19p, 12-month range 4.22p-15.76p. The clinical stage drug development company is "surprised and disappointed" after being informed that independent data management committee concludes analyses of SFX-01 in Star Covid-19 study did not meet the interim futility hurdle required to continue the study, and that active treatment would not be likely to show an overall statistically significant improvement. Recruitment into trial to be halted. "We are surprised and disappointed by these findings given the strong preclinical hypothesis surrounding sulforaphane as an Nrf2 activator with potential direct antiviral properties," says Chief Executive Huw Jones.

----------

Empyrean Energy PLC, down 24% at 6.43p, 12-month range 3.05p-9p. The oil and gas development company raises GBP5.0 million via placing of 83.7 million shares at price of 6.0p each. "Funds raised under this placing will primarily be used to secure a suitable drilling rig and order long lead items and for the Company's general working capital requirements as it prepares to drill the Jade prospect at its 100% owned Block 29/11 license in China, scheduled for late 2021," it says.

----------

Ilika PLC, down 24% at 153p, 12-month range 56.4p-285p. The advanced solid-state battery company plans placing of up to 12.8 million shares at price of 140p each to raise GBP18.0 million. Also intends to raise up to further GBP3.7 million through open offer, and will also make retail offer for up to GBP3.0 million via PrimaryBid. In total, eyes raising total gross proceeds of GBP24.7 million. "The net proceeds of the capital raising are expected to support the development of Ilika's solid-state electric vehicle pouch cells through its Goliath programme until the programme reaches and exceeds Lithium Ion Battery equivalence," it says.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
1 Jun 2022 11:45

Open Orphan's hVIVO wins GBP14.7 million influenza study contract

(Alliance News) - Open Orphan PLC on Wednesday said it's subsidiary hVIVO signed a GBP14.7 million contract for an influenza characterisation study and a follow on influenza human challenge study.

Read more
31 May 2022 16:05

UK earnings, trading statements calendar - next 7 days

Wednesday 1 June  
Impax Asset Management Group PLCHalf Year Results
Dr Martens PLCFull Year Results
Thursday 2 June  
no events scheduled 
Friday  3 June  
no events scheduled  
Monday 6 June  
Atrato Onsite Energy PLCHalf Year Results
Empiric Student Property PLCTrading Statement
Jadestone Energy PLCFull Year Results
Tuesday 7 June  
Gooch & Housego PLCHalf Year Results
LXi REIT PLCFull Year Results
NewRiver REIT PLCFull Year Results
Open Orphan PLCFull Year Results
Schroder Real Estate Investment Trust LtdFull Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
18 May 2022 16:43

Open Orphan's hVIVO wins GBP7.3 million influenza study contract

(Alliance News) - Open Orphan PLC on Wednesday said its subsidiary hVIVO Ltd has signed a GBP7.3 million contract.

Read more
18 May 2022 15:15

Open Orphan wins £7.3m human flu study contract

(Sharecast News) - Specialist contract research organisation Open Orphan announced on Wednesday that its hVIVO subsidiary has signed a £7.3m flu human challenge study contract with an unnamed biotechnology company, to test its antiviral product using hVIVO's influenza human challenge study model.

Read more
6 May 2022 19:11

TRADING UPDATES: Enwell pleased with SV-31; SDX Energy ties in well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
5 May 2022 14:53

IN BRIEF: Open Oprhan wins contract for vaccine field site study

Open Orphan PLC - London-based pharmaceutical services - Subsidiary hVIVO is awarded new study with existing unnamed pharmacetical client to act as vaccination site for the client's respiratory syncytial virus vaccine candidate. hVIVO's specialist arm FluCamp will recruit 60 healthy volunteers to the new site clinic at Plumbers Row where trials will take place.

Read more
13 Apr 2022 19:46

TRADING UPDATES: McKay backs Workspace offer; IOG fixes Blythe fault

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
1 Apr 2022 20:23

IN BRIEF: Open Orphan Covid study results published in Nature Medicine

Open Orphan PLC - London-based pharmaceutical services - Says Thursday that results from the world's first Covid-19 characterisation study have been peer reviewed and published in the scientific journal Nature Medicine. Says study showed the SARS-CoV-2 human challenge was safe in healthy young adults and provided insights into the course of Covid-19 infection with potential positive public health implications. With the characterisation study disease modelling data completed, and human challenge model established, Open Orphan says it should be able to conduct Covid-19 human challenge studies in 2022.

Read more
25 Mar 2022 14:10

IN BRIEF: Open Orphan wins GBP5 million human challenge study pact

Open Orphan PLC - London-based pharmaceutical services firm - Says its subsidiary, hVIVO, wins contract with a European biotechnology company for a human challenge study. The GBP5 million contract with a European biotech seeks to test hVIVO's intravenous antiviral candidate. The study on the respiratory syncytial virus is expected to commence this year. Revenue from the deal will be recognised across 2022 and 2023.

Read more
25 Mar 2022 09:39

Open Orphan wins £5m contract for human study in RSV

(Sharecast News) - Open Orphan announced on Friday that its hVIVO subsidiary has signed a £5m respiratory syncytial virus (RSV) human challenge study contract with an unnamed European biotechnology company, to test its intravenous antiviral candidate.

Read more
8 Mar 2022 19:37

IN BRIEF: Open Orphan expects to report profitable 2021 performance

Open Orphan PLC - London-based pharmaceutical services - For 2021, expects to report earnings before interest, tax, depreciation and amortisation, on revenue which is set to be GBP40 million, up from GBP20.6 million in 2020. For 2022, the company is targeting GBP50 million in non-Covid work revenue.

Read more
24 Feb 2022 15:24

Open Orphan appoints Mo Khan as its new chief executive

(Sharecast News) - Contract research organisation Open Orphan announced the appointment of Yamin 'Mo' Khan as its chief executive officer on Thursday, with immediate effect.

Read more
24 Feb 2022 14:48

IN BRIEF: Open Orphan non-exec Mo Khan switches to chief executive

Open Orphan PLC - London-based pharmaceutical services - Moves Non-Executive Director Mo Khan to chief executive officer, effective immediately. Khan had joined the Open Orphan board back in October. The company notes he has 25 years of clinical research experience. Cathal Friel remains executive chair, while Open Orphan will aim to find a new independent non-executive director within the next six months.

Read more
22 Feb 2022 21:57

TRADING UPDATES: Angling Direct ups revenue; Ceiba takes Omicron hit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
17 Feb 2022 20:13

IN BRIEF: Positive results from Open Orphan human challenge study

Open Orphan PLC - pharmaceutical services provider - Sees positive results from a human challenge study assessing its respiratory syncytial virus antiviral candidate, EDP-938. Says results from the study have been published in The New England Journal of Medicine. hVIVO, a subsidiary of Open Orphan, conducted the Phase 2a, double-blind, placebo-controlled trial.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.